OBJECTIVE: To explore the relationship between endothelial nitric oxide synthase (eNOS) activity, insulin resistance and macrovascular disease in patients with acute myocardial infarction (AMI). METHODS: AMI patients were grouped according to the presence (group A, n = 49) or absence (group B, n = 48) of macrovascular disease. A healthy control group was also recruited (group C, n = 43). eNOS activity and nitric oxide (NO), endothelin-1 (ET-1), fasting plasma glucose and fasting insulin levels were compared across groups. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated in each participant and correlations between biochemical parameters were determined. RESULTS: eNOS and NO levels were significantly lower in group A compared with the other groups. Conversely, ET-1 levels and the HOMA-IR were significantly higher in group A. eNOS activity and NO levels were significantly lower, and ET-1 levels and HOMA-IR were significantly higher, in group B compared with controls. Across the groups there were inverse correlations in AMI patients between eNOS and HOMA-IR, NO and HOMA-IR, eNOS and ET-1, and NO and ET-1, and positive correlations between eNOS and NO, regardless of whether macrovascular disease was present. CONCLUSION: There is a close relationship between eNOS activity and the development of insulin resistance and macrovascular disease in AMI patients.
Introduction
Acute myocardial infarction (AMI) is a serious life-threatening condition that is associated with the development of atherosclerosis. 1 Atherosclerosis represents the major macrovascular pathology in patients with AMI 2 and is associated with changes such as endothelial intimal thickening, fatty-streak and fibrous-cap formation, and plaque rupture. 3 Nitric oxide (NO), which is produced by the action of endothelial nitric oxide synthase (eNOS) 4 in the vascular endothelium, is a potent antiatherosclerotic factor. 5 Together, NO and eNOS and insulin resistance in AMI the potent vasoconstrictor endothelin-1 (ET-1) act as a pair of mutually constraining factors to play a key role in the regulation of vascular tone. An imbalance in either of these opposing factors can result in disease development. 6 Insulin resistance -which can lead to high blood pressure, 7 diabetes, 8 obesity 8, 9 and a series of metabolic syndromes 10 -has also been implicated in the development of atherosclerosis. 11 There is evidence that reduced insulin sensitivity and impairment of insulin receptor-dependent signalling through phosphatidylinositol-3 kinase leads to a decrease in endothelial NO synthesis and release, resulting in atherosclerotic changes that are pathological. 12 This study explored the relationship between eNOS activity in the peripheral blood and the occurrence of insulin resistance in patients with AMI, with or without macrovascular disease.
Patients and methods

STUDY POPULATION
Patients with AMI who attended the Department of Cardiology, Heilongjiang Provincial Hospital between June 2010 and June 2011 were enrolled sequentially into this study. Patients were recruited and blood sampling was completed within the first 24 h after infarction. Patients were selected using universal diagnostic criteria for AMI 13 that included a history of typical angina, high levels of creatinine kinase (CK) and the CK-MB isoenzyme, dynamic ST-T evolution and positive plasma troponin. Patients with AMI were divided into two groups: AMI with macrovascular disease (group A) and AMI without macrovascular disease (group B). Patients in group A were required to meet at least one of the following criteria: a colour Doppler ultrasound examination revealing bilateral lower extremity or bilateral carotid artery atherosclerotic plaque formation, thrombosis or irregular arterial stenosis; symptoms of poor leg circulation, such as intermittent claudication and ischaemic pain; history of cerebral infarction or lesions suggestive of ischaemia, as determined by brain computed tomography (CT) scanning or magnetic resonance imaging (MRI). A control group (group C), consisting of healthy individuals from the Heilongjiang Provincial Hospital Medical Centre with no family history of diabetes or hypertension, who were attending the hospital for routine examinations, was also recruited into the study. Control subjects underwent the following examinations: an oral glucose tolerance test to exclude diabetes; an electrocardiogram and a cardiac ultrasound to exclude the presence of coronary artery disease;
CT, MRI, and ultrasound examinations to exclude any major vascular diseases. Patients and control subjects were not included in the study if they had a history of: cancer within the previous 5 years; severe liver disease, nephrotic syndrome, an infectious disease, recent trauma and/or surgery within 1 year of study entry; a history of mental illness.
All patients and controls provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki (2008) and was approved by the Ethics Committee of the First Hospital, Jilin University, China (permit number: 20070206008); this Ethics Committee covers approvals of studies conducted at Heilongjiang Provincial Hospital.
BIOCHEMICAL MEASUREMENTS
Blood samples (3 ml) were collected in heparin tubes (15 IU/ml) for plasma separation or in tubes without anticoagulant for serum separation from patients with AMI in the morning after 24 h of fasting, and eNOS and insulin resistance in AMI from healthy controls in the morning of the day of physical examination (after 8 h of fasting). The serum was separated from peripheral blood by centrifugation at 3000 g for 20 min. AMI patients did not undergo a physical examination. Plasma and serum samples were stored at −20°C until analysis.
Fasting plasma glucose was measured by the glucose oxidase method using an Olympus ® AU-5400™ automatic biochemical analyser (Diamond Diagnostics, Holliston MA, USA) and fasting insulin was measured by radioimmunoassay (Linco Research, St Charles, MO, USA) according to the manufacturer's instructions. The degree of insulin resistance was calculated using the homeostasis model assessment of insulin resistance (HOMA-IR), based on the formula of Matthews et al: 14 HOMA-IR = fasting insulin (mIU/l) × fasting plasma glucose (mmol/l)/22.5.
Activity of eNOS was determined using a commercially available NO nitrate reductase colorimetric assay kit (Nanjing Bioengineering Institute, Nanjing City, China) according to the manufacturer's instructions. To measure total NO, 1 U of enzyme activity was defined as 1 ml of serum generating 1 nmol NO at 1 min.
Plasma ET-1 was determined using a radioimmunoassay kit (Nanjing Bioengineering Institute) according to the manufacturer's instructions; within-batch variations in ET-1 levels measured by the kit were < 10% and between-batch variations were < 15%.
STATISTICAL ANALYSES
All data were analysed using SPSS ® statistical software, version 12.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Normally distributed data were expressed as mean ± SD, and nonnormal data were log-transformed into approximate normal distributions. Differences between groups were determined using Student's t-test for continuous data or the χ 2test for categorical data. Correlations between biochemical measures in each group were analysed using Pearson's correlation coefficient. A P-value < 0.01 was considered to be statistically significant.
Results
A total of 97 patients with AMI were recruited into this study. Group A included 49 patients (26 males and 23 females) with AMI and macrovascular disease, with a mean ± SD age of 56.0 ± 6.1 years (age range 40 -70 years). Group B included 48 patients (25 males and 23 females) with AMI but without macrovascular disease, with a mean ± SD age of 55.1 ± 6.9 years (age range 41 -70 years). Group C included 43 healthy individuals (22 males and 21 females) with a mean ± SD age of 54.8 ± 7.4 years (age range 40 -69 years). There were no significant differences between groups with respect to gender, age, body mass index, blood lipid levels or lifestyle (data not shown).
Comparisons of biochemical parameters across the three study groups are shown in Table 1 . Compared with the healthy controls, fasting plasma glucose and fasting insulin levels, and the HOMA-IR, were all significantly higher in patients with AMI, regardless of the presence of macrovascular disease (P < 0.01). In group A, levels of fasting insulin and the HOMA-IR were significantly higher than in group B (P < 0.01), while fasting plasma glucose levels were similar in groups A and B. Compared with group C, eNOS activity and NO levels were significantly lower in groups A and B (P < 0.01); levels of these biochemical parameters were also significantly lower in group A than in group B (P < 0.01). Levels of ET-1 were significantly higher in groups A and B compared with group C (P < 0.01), and eNOS and insulin resistance in AMI 
TABLE 1: Comparison of fasting plasma glucose, fasting insulin, degree of insulin resistance (homeostasis model assessment of insulin resistance [HOMA-IR]), endothelial nitric oxide synthase (eNOS) activity, nitric oxide (NO) and endothelin-1 (ET-1) levels in peripheral blood between patients with acute myocardial infarction, with (group A) or without (group B) macrovascular disease, and healthy control subjects (group C) eNOS and insulin resistance in AMI
in group A compared with group B (P < 0.01). Correlation coefficients between biochemical parameters in each study group are shown in Table 2 . There were inverse correlations between the following parameters in patients with AMI, regardless of the presence or absence of macrovascular disease: eNOS and HOMA-IR; NO and HOMA-IR; eNOS and ET-1; and NO and ET-1. Inverse correlations were also found between eNOS and ET-1, and NO and ET-1, in group C. There were positive correlations between eNOS and NO in all three study groups. All correlations were statistically significant (P < 0.01).
Discussion
The mechanism underlying insulin resistance is complicated and, despite extensive research over the last several decades, it is still not fully understood. Insulin resistance demonstrates significant heterogeneity, 15 with mechanisms varying under different pathological conditions. 16 Regardless of its heterogeneous nature, insulin resistance is, ultimately, caused by functional defects in insulin actions at target tissues and receptors. 17 Patients with insulin resistance have an increased risk of coronary atherosclerosis. 18 It has been reported that insulin increases NO release in the endothelium to mediate vasodilation, rather than by acting to increase the sensitivity of vascular smooth muscle to the relaxant effects of NO. 19 The key enzyme involved in the generation of NO is NOS. There are three known NOS isomers: neuronal NOS (nNOS), eNOS, and inducible NOS (iNOS). 20 Among these, nNOS is highly expressed in skeletal muscle and nervous system cells, 21 while iNOS expression is high in activated macrophages 22 and eNOS is predominantly expressed in vascular endothelial cells. 23 The current study indicated a common mechanism of insulin resistance in patients with AMI, regardless of the presence or absence of macrovascular disease. In patients with AMI, fasting plasma glucose, fasting insulin and HOMA-IR values were significantly higher, and eNOS and NO levels were significantly lower, compared with levels in healthy controls. Patients with macrovascular disease had lower levels of eNOS activity and NO compared with patients without macrovascular disease. The concentration of ET-1 was significantly higher in patients with AMI compared with the healthy controls, and in patients with AMI who had macrovascular disease versus those without macrovascular disease. Correlation analyses showed that eNOS activity and NO were inversely correlated with HOMA-IR in patients with AMI, whereas there was a positive correlation between eNOS and NO in all three groups. The results also showed an inverse correlation between eNOS and ET-1, and between NO and ET-1, in all three groups. These data suggest that these parameters could potentially be used as diagnostic markers in patients with AMI, and that an increase in ET-1 concentration may be a risk factor for the development of insulin resistance in patients with AMI, or for the development of macrovascular disease in patients with insulin resistance. Measurement of the ET-1 level could, therefore, be a beneficial addition to the clinical analyses undertaken in patients with AMI who also have insulin resistance and macrovascular disease.
Insulin resistance has rarely been studied in patients with AMI. The present study demonstrated the occurrence of insulin resistance in these patients, regardless of the presence or absence of macrovascular disease. In addition, this investigation showed that eNOS activity and NO levels were significantly decreased in these patients, and were inversely correlated with HOMA-IR, indicating a higher level of endothelial dysfunction with increasing insulin resistance. Furthermore, patients with AMI and macrovascular disease had more marked insulin resistance and a greater degree of endothelial dysfunction than patients without macrovascular disease. This study confirms the relationship between insulin resistance, eNOS activity and the development of macrovascular disease.
